Drugs / MDCO-2010
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01530399 | Mar → Nov 2012 | hemorrhagic disease | The Medicines Company | Terminated | No outcome recorded |
| Phase 2 | NCT01535222 | Nov 2010 → May 2011 | coronary artery disorder | The Medicines Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDCO-2010 | “MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure.” NCT01530399 ↗ |
| Action | Inhibit | “is a direct inhibitor of plasmin and plasma kallikrein” NCT01535222 ↗ |
| Modality | Small molecule | “MDCO-2010, a synthetic small molecule” NCT01535222 ↗ |